The evolution of the major variants, including the delta mutation.
Understanding the potential and limitations of new Acinetobacter baumannii active therapies.
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
Matthew Hepburn, MD, offers some insights on his time as vaccine development lead for Operation Warp Speed and the ability to develop a COVID-19 vaccine within a year.
Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.
A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
A recent study emphasizes the genetic diversity within the ompA-genotype L2b clade, enhancing our understanding of sexually transmitted infections and how they are transmitted.
The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.
Timmy Do, PharmD, BCIDP, BCPS, presents case series at MAD-ID 2025 on investigational therapies following tecovirimat failure.
Investigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.
Rising temperatures and changing humidity are undermining natural pest control, putting North American forests at risk.
Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.
Unique challenges can affect the success of the shift from pediatric to adult care settings.
Significant value can be offered through the incorporation of stewardship concepts into infection guidelines, but we must also address the risk and challenges it may impose on health care systems.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.
There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.
Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.
Here are some insights into this upcoming 2021-2022 influenza season as well as concerns of the twindemic and addressing both the seasonal and pandemic viruses simultaneously.
Sean Tucker, PhD, highlights effective immune response and mucosal immunity, paving the way for broader applications in viral disease prevention.
With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.